TrialPath

15 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

13 studies on the map

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis — Northwestern Memorial Hospital, ChicagoOcrelizumab Discontinuation in Relapsing Multiple Sclerosis — Yale School of Medicine, New HavenProspective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod — University of Colorado Anschutz Medical Campus, AuroraProcesses and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression — Laureate Institute for Brain Research, TulsaAcute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A) — University of Cincinnati, CincinnatiPharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE) — University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, CincinnatiTrial With the Treatment of Sertraline in Youth With Generalized, Separation and/or Social Anxiety Disorders. — University of Cincinnati, CincinnatiSelf-Adjusted Nitrous Oxide: A Feasibility Study in the Setting of Vasectomy — Beth Israel Deaconess Medical Center, BostonGlucose Consumption in MS Using [F-18]FDG-PET — Brigham & Women's Hospital, BostonDalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis — MGH Institute of Health Professions, BostonSilodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis — Atlantic Health, MorristownHome Based Infusions for Ocrelizumab — Amerita, CentennialStudy of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis — Johns Hopkins University, Baltimore